Next-Generation Targeted Therapy NTS071 Enters Clinical Trials, Now Recruiting Patients with Advanced Solid Tumors Harboring TP53 Y220C Mutation

Nov 06, 2025 23:59 CST Updated 23:59

NUTSHELL

Allosteric Drug Developer

NTS071, developed by NUTSHELL Therapeutics Inc. using its self-developed AI + allosteric molecule platform ALLOSTARTM, combines sophisticated structure-based drug design and molecular optimization technologies. NTS071 demonstrates Best-in-Class preclinical properties among similar products targeting the same site. NTS071 exhibits picomolar-level biochemical activity, surpassing the clinical molecule PC14586 from the original developer PMV by 20-fold. Moreover, NTS071 shows enhanced stability in liver microsomes and hepatocytes across various species. In preclinical PK tests in all species, NTS071 demonstrates lower in vivo clearance and higher oral exposure compared to PC14586. NTS071 also has a relatively low plasma protein binding rate and a higher proportion of free drug, which supports in vivo efficacy. Additionally, NTS071 addresses the CYP3A4 inhibition issue associated with PC14586, presenting a lower risk of drug-drug interactions. NTS071 has also shown excellent safety in non-clinical toxicology studies, with a very wide safety margin.

Now, this new anti-cancer drug has officially entered clinical trials! Patients in China can now access it throughGlobal Oncology Doctors Network Medical Department (4006667998), understand the detailed inclusion and exclusion criteria, or preliminarily assess whether you qualify for participation.

Introduction to Anti-Cancer Projects

Drug Name：NTS071；

Staging:ⅠPeriod,Phase Ⅱ；

Lines of Treatment:StandardTreatTherapy LossDefeat;

Mutated Gene:No Target Requirements。

Which patients are suitable?

Applicable toPatients with locally advanced or metastatic solid tumors carrying the TP53 Y220C mutation.

Inclusion Criteria (Partial)

AffectedTesterMustMustSymbolCombinedInAll standards below must be met to enter this study:

1) Aged 18 years or older, gender不限;

2) A test report showing the presence of the TP53 Y220C mutation in locally advanced or metastatic solid tumors (confirmed in tumor tissue or ctDNA);

3) Have received at least one prior line of anti-tumor treatment and experienced disease progression;

4) According to the RECIST 1.1 criteria, there must be at least one measurable lesion;

5）ECOG PSThe score is 0-1.

Exclusion Criteria (Partial)

RecipientTestPatientMustMustSymbolCombineInAll standards below must be met to enter this study:

1）Participated in other clinical trials within 28 days prior to the first dose;

2）Received anticancer therapy (chemotherapy, immunotherapy, hormone therapy, targeted therapy, biologic therapy, or other anticancer therapies) within 28 days or 5 half-lives of the investigational drug prior to the first dose;

3）Received traditional Chinese medicine with anti-tumor effects within 14 days before the first dose;

4）Use of any medication with QTc prolongation effects within 14 days prior to the first dose;

5）Received radical radiotherapy within 4 weeks before the first dose, or received palliative radiotherapy within 7 days before the first dose;

6）Major surgery within 4 weeks prior to the first dose or expected during the study period.

Project Implementation Region

The study is currentlyTo be carried out in the following areas: Shanghai, Shaanxi, Beijing, etc. Specific details will be confirmed upon later consultation.

Summary of Required Documents to Submit

The materials that patients need to prepare and submit include:Pathology Report, Gene Test Report, Admission Record, Discharge Summary, CT/MRI Examination, Complete Blood Count, Liver and Kidney Function, Coagulation Function, Infectious Disease Screening, Electrocardiogram Reportetc.

Global Oncology Department Warm Reminder

If you wantParticipate in this itemClinical research, or wantFor more information about NTS071, please contactGlobal Cancer Doctors Network Medical Department (400-666-7998), obtain more information about applications both in China and abroad, or apply directly. We promise to keep all participants' personal information confidential and ensure compliance with national laws and regulations related to clinical research throughout the entire process.

#Ark Gene Treasure Plan#

"Ark Gene Treasure Plan" is a gene "treasure hunt" initiative launched by Global Cancer Doctors Network in collaboration with Cancer-Free Home, authoritative gene testing institutions, international pharmaceutical companies, and renowned cancer centers. This plan aims to thoroughly explore the survival hopes indicated in each gene testing report, comprehensively interpret the gene testing reports for cancer patients, and match cancer patients with suitable newly approved drugs and ongoing clinical trials of investigational drugs on a global scale, providing patients with new survival opportunities as well as chances for free treatment with approved or unapproved new drugs!

Patients who wish to participate can send their genetic test reports and diagnostic reports electronically.Sub-version or ShotIlluminateSend to: doctor.huang@globecancer.com. Leave your contact information in the email, and the Medical Department will contact you by phone within 1 working day after receiving and analyzing the report; or call directly.Global Cancer Doctors Network Medical Department (400-666-7998)Evaluation.

This article is original content from Global Oncologist Network. Reproduction is strictly prohibited without authorization.

Scan to Add Patient Group

Cancer Fighting News｜New Technologies｜New Drug Development｜Authoritative Experts

Join the group to receive free anti-cancer resources

Patient Concerns